Alyeska Investment Group LP Raised By $42.76 Million Its F5 Networks (FFIV) Stake; 4 Analysts Bullish Amphastar Pharmaceuticals (AMPH)

July 14, 2017 - By Winifred Garcia

Alyeska Investment Group Lp increased F5 Networks Inc (FFIV) stake by 350.86% reported in 2016Q4 SEC filing. Alyeska Investment Group Lp acquired 296,977 shares as F5 Networks Inc (FFIV)’s stock declined 11.30%. The Alyeska Investment Group Lp holds 381,620 shares with $55.23 million value, up from 84,643 last quarter. F5 Networks Inc now has $7.96B valuation. The stock declined 3.37% or $4.32 reaching $123.97 on the news. About 1.83M shares traded or 184.44% up from the average. F5 Networks, Inc. (NASDAQ:FFIV) has risen 21.28% since July 14, 2016 and is uptrending. It has outperformed by 4.58% the S&P500.

Among 5 analysts covering Amphastar Pharmaceuticals (NASDAQ:AMPH), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Amphastar Pharmaceuticals had 10 analyst reports since August 10, 2015 according to SRatingsIntel. Zacks upgraded Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) on Tuesday, August 18 to “Hold” rating. The rating was initiated by BMO Capital Markets with “Market Perform” on Wednesday, June 29. The firm has “Buy” rating by Zacks given on Monday, August 10. The rating was maintained by Jefferies with “Buy” on Tuesday, August 9. The stock of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) has “Buy” rating given on Tuesday, January 19 by Jefferies. Jefferies maintained the stock with “Buy” rating in Friday, June 9 report. The stock of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) earned “Outperform” rating by Wells Fargo on Friday, February 19. Needham maintained Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) on Tuesday, May 10 with “Buy” rating. The rating was downgraded by Raymond James to “Outperform” on Tuesday, March 14. See Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) latest ratings:

09/06/2017 Broker: Jefferies Rating: Buy New Target: $20.0000 Maintain
14/03/2017 Broker: Raymond James Old Rating: Strong Buy New Rating: Outperform Old Target: $21.00 New Target: $18.00 Downgrade

Since February 1, 2017, it had 0 insider buys, and 13 selling transactions for $9.54 million activity. 2,402 shares valued at $306,949 were sold by Rogers Scot Frazier on Monday, May 1. 4,473 shares valued at $591,878 were sold by EAMES EDWARD JULIAN on Wednesday, February 1. The insider MCADAM JOHN sold 21,862 shares worth $3.05 million. Chadwick Jonathan sold $541,698 worth of F5 Networks, Inc. (NASDAQ:FFIV) on Tuesday, February 7. $108,248 worth of stock was sold by Kearny Ryan C. on Monday, May 1. $844,513 worth of F5 Networks, Inc. (NASDAQ:FFIV) was sold by Reinland Andrew. DiLullo John D also sold $436,461 worth of F5 Networks, Inc. (NASDAQ:FFIV) on Monday, May 1.

Investors sentiment increased to 0.93 in Q4 2016. Its up 0.10, from 0.83 in 2016Q3. It is positive, as 41 investors sold FFIV shares while 197 reduced holdings. 71 funds opened positions while 151 raised stakes. 60.27 million shares or 2.18% more from 58.99 million shares in 2016Q3 were reported. Jefferies Group Inc Ltd Liability Corporation holds 0.02% or 20,964 shares. Capstone Asset Mngmt stated it has 0.05% of its portfolio in F5 Networks, Inc. (NASDAQ:FFIV). Stevens Cap Mgmt LP stated it has 30,472 shares. Tiaa Cref Investment Mgmt Ltd Liability Co stated it has 623,492 shares or 0.07% of all its holdings. Ww Asset Inc has invested 0.03% in F5 Networks, Inc. (NASDAQ:FFIV). Savings Bank Of Montreal Can holds 1.28 million shares or 0.19% of its portfolio. Exxonmobil Inv Management Inc Tx owns 15,118 shares. Utd Automobile Association stated it has 0.09% of its portfolio in F5 Networks, Inc. (NASDAQ:FFIV). Advantus Cap reported 6,565 shares. Bridgeway Capital Management owns 0.11% invested in F5 Networks, Inc. (NASDAQ:FFIV) for 57,800 shares. Metropolitan Life Ins New York holds 35,384 shares. Selway Asset Management accumulated 13,685 shares. Todd Asset Mngmt Limited Com accumulated 1.89% or 435,828 shares. Airain Limited owns 0.5% invested in F5 Networks, Inc. (NASDAQ:FFIV) for 43,042 shares. Fdx Advsrs Inc has 0.03% invested in F5 Networks, Inc. (NASDAQ:FFIV).

Alyeska Investment Group Lp decreased Kar Auction Svcs Inc (NYSE:KAR) stake by 825,676 shares to 280,032 valued at $11.94 million in 2016Q4. It also reduced Group 1 Automotive Inc (NYSE:GPI) stake by 96,904 shares and now owns 19,752 shares. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) was reduced too.

Among 31 analysts covering F5 Networks Inc. (NASDAQ:FFIV), 6 have Buy rating, 2 Sell and 23 Hold. Therefore 19% are positive. F5 Networks Inc. had 70 analyst reports since July 24, 2015 according to SRatingsIntel. Nomura upgraded the shares of FFIV in report on Wednesday, November 9 to “Neutral” rating. The firm has “Outperform” rating by Oppenheimer given on Wednesday, September 14. Barclays Capital initiated F5 Networks, Inc. (NASDAQ:FFIV) rating on Wednesday, October 14. Barclays Capital has “Equalweight” rating and $131 target. The stock of F5 Networks, Inc. (NASDAQ:FFIV) earned “Sector Perform” rating by RBC Capital Markets on Thursday, October 29. The stock has “Mkt Perform” rating by Bernstein on Wednesday, November 30. The stock of F5 Networks, Inc. (NASDAQ:FFIV) has “Sector Weight” rating given on Tuesday, May 17 by Pacific Crest. RBC Capital Markets maintained F5 Networks, Inc. (NASDAQ:FFIV) on Monday, May 29 with “Hold” rating. The stock of F5 Networks, Inc. (NASDAQ:FFIV) earned “Neutral” rating by Buckingham Research on Thursday, April 21. The stock of F5 Networks, Inc. (NASDAQ:FFIV) earned “Mkt Perform” rating by Raymond James on Friday, September 25. Jefferies maintained the shares of FFIV in report on Friday, June 16 with “Hold” rating.

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company has market cap of $813.68 million. The Firm focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. It has a 93.57 P/E ratio. The Firm has two divisions: finished pharmaceutical products and active pharmaceutical ingredients products.

About 84,454 shares traded. Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) has risen 8.19% since July 14, 2016 and is uptrending. It has underperformed by 8.51% the S&P500.